Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.

摘要: Abstract Background The prognostic and predictive abilities of 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) coupled with conventional computed (CT) have not been studied in patients unresectable colorectal liver metastases (uCRLM) treated combined hepatic arterial infusion (HAI) systemic chemotherapy. Objectives ability PET‐CT metabolic response parameters to predict conversion resectability oncologic outcome this setting was evaluated. Methods Thirty‐eight undergoing serial as part a Phase II trial HAI chemotherapy for uCRLM were included. Metabolic determined the percentage change standard uptake value (SUV) total lesion glycolysis (TLG). Conversion resection, overall survival (OS), progression‐free (PFS) recurrence‐free evaluated using statistics. Results Volumetric sufficient facilitate resection seen 53% after median 5 months therapy. Median follow‐up 38 months (range: 32–52 months). OS reached [95% confidence interval (CI) 32 months–unknown] 3‐year 54% 33–71%). PFS 13 months (95% CI 6–21 months) 3 year 10% 3–20%). Neither baseline values nor any correlated variables or recurrence on Cox regression analysis. Conclusions Pre‐ post‐treatment PET‐related do should be used monitor determine prognosis these patients.